Randomized withdrawal of long‐term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Rheumatology
- Vol. 36 (5), 351-358
- https://doi.org/10.1080/03009740701394021
Abstract
Objective: Short‐term, low‐dose glucocorticoid (GC) treatment has anti‐inflammatory and disease‐modifying effects in rheumatoid arthritis (RA). However, scientific support for long‐term, low‐dose GC treatment, although widespread, is poor, and information on the effects on bone density is scarce. The aim of this study was to investigate how long‐term GC treatment in RA affects inflammation as well as bone density, and also to investigate the feasibility of withdrawal of GC. Patients and methods: Fifty‐eight patients with RA treated with 5–7.5 mg prednisolone daily for at least 2 years were randomized either to withdraw or to continue GC treatment. The patients were followed prospectively for 2 years with respect to disease activity [using the Disease Activity Score calculated for 28 joints, (DAS28)], functional ability [using the Health Assessment Questionnaire (HAQ) score] and bone mineral density (BMD) of the lumbar spine and hip. Results: Only 11 patients out of 26 randomized to stop GC treatment and available for outcome measures succeeded in stopping the GC medication within 1 year. Fifteen patients failed withdrawal of GC because of increased joint symptoms. A higher mean DAS28 during the study was associated with loss of bone mass in the trochanter. The group that continued with unchanged GC treatment did not deteriorate in BMD during the 2 years but in fact Z‐scores improved significantly. Conclusion: Our results indicate that low‐dose GC treatment after several years has persisting anti‐inflammatory effects in RA and no further negative impact on BMD. It thus seems to be more important to control disease activity than withdraw low‐dose GC treatment in this population considering bone health.Keywords
This publication has 34 references indexed in Scilit:
- The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritisScandinavian Journal of Rheumatology, 2005
- Fifty Years of Experience with Cortisone Therapy in the Study and Treatment of Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2002
- Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAnnals of Internal Medicine, 2002
- Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology, 2000
- Can We Use Steroid Hormones to Immunomodulate Rheumatic Diseases? Rheumatoid Arthritis as an ExampleAnnals of the New York Academy of Sciences, 1999
- Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study GroupRheumatology, 1998
- Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritisBMJ, 1998
- Low‐dose corticosteroids in rheumatoid arthritis. A meta‐analysis of their moderate‐term effectivenessArthritis & Rheumatism, 1996
- The Effect of Glucocorticoids on Joint Destruction in Rheumatoid ArthritisNew England Journal of Medicine, 1995
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsAmerican Journal Of Medicine, 1994